

Resource Summary Report

Generated by [FDI Lab - SciCrunch.org](#) on Apr 28, 2025

APC anti-mouse CD4

RRID:AB_312718

Type: Antibody

Proper Citation

(BioLegend Cat# 100515, RRID:AB_312718)

Antibody Information

URL: http://antibodyregistry.org/AB_312718

Proper Citation: (BioLegend Cat# 100515, RRID:AB_312718)

Target Antigen: CD4

Host Organism: rat

Clonality: monoclonal

Comments: Applications: FC

Antibody Name: APC anti-mouse CD4

Description: This monoclonal targets CD4

Target Organism: mouse

Clone ID: Clone RM4-5

Antibody ID: AB_312718

Vendor: BioLegend

Catalog Number: 100515

Alternative Catalog Numbers: 100516

Record Creation Time: 20231110T045028+0000

Record Last Update: 20241114T235615+0000

Ratings and Alerts

No rating or validation information has been found for APC anti-mouse CD4.

No alerts have been found for APC anti-mouse CD4.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 15 mentions in open access literature.

Listed below are recent publications. The full list is available at [FDI Lab - SciCrunch.org](#).

Mucciolo G, et al. (2024) EGFR-activated myofibroblasts promote metastasis of pancreatic cancer. *Cancer cell*, 42(1), 101.

Horikawa I, et al. (2024) Chronic stress alters lipid mediator profiles associated with immune-related gene expressions and cell compositions in mouse bone marrow and spleen. *Journal of pharmacological sciences*, 154(4), 279.

Chen L, et al. (2024) Palmitoylation alters LDHA activity and pancreatic cancer response to chemotherapy. *Cancer letters*, 587, 216696.

Fontana P, et al. (2024) Small-molecule GSDMD agonism in tumors stimulates antitumor immunity without toxicity. *Cell*, 187(22), 6165.

Mortales C, et al. (2023) NL-201 Upregulates MHC-I Expression and Intratumoral T-cell Receptor Diversity, and Demonstrates Robust Antitumor Activity as Monotherapy and in Combination with PD-1 Blockade. *Cancer immunology research*, 11(7), 1000.

Elshikha AS, et al. (2023) Pharmacologic inhibition of glycolysis prevents the development of lupus by altering the gut microbiome in mice. *iScience*, 26(7), 107122.

Srivastava P, et al. (2023) Peripheral MC1R Activation Modulates Immune Responses and is Neuroprotective in a Mouse Model of Parkinson's Disease. *Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology*, 18(4), 704.

Li Y, et al. (2022) Histone methylation antagonism drives tumor immune evasion in squamous cell carcinomas. *Molecular cell*, 82(20), 3901.

Mudalagiriappa S, et al. (2022) GM-CSF+ Tc17 cells are required to bolster vaccine immunity against lethal fungal pneumonia without causing overt pathology. *Cell reports*, 41(4), 111543.

Wang W, et al. (2022) Mobilizing phospholipids on tumor plasma membrane implicates phosphatidylserine externalization blockade for cancer immunotherapy. *Cell reports*, 41(5), 111582.

Nahrendorf W, et al. (2021) Inducible mechanisms of disease tolerance provide an alternative strategy of acquired immunity to malaria. *eLife*, 10.

Imanishi T, et al. (2020) mTORC1 Signaling Controls TLR2-Mediated T-Cell Activation by Inducing TIRAP Expression. *Cell reports*, 32(3), 107911.

Yang BH, et al. (2019) TCF1 and LEF1 Control Treg Competitive Survival and Tfr Development to Prevent Autoimmune Diseases. *Cell reports*, 27(12), 3629.

Uchil PD, et al. (2019) A Protective Role for the Lectin CD169/Siglec-1 against a Pathogenic Murine Retrovirus. *Cell host & microbe*, 25(1), 87.

Arima Y, et al. (2017) Brain micro-inflammation at specific vessels dysregulates organ-homeostasis via the activation of a new neural circuit. *eLife*, 6.